Worker Protection from Heat Stress: Now More Than Ever, It's Up to Employers to Do The Right Thing
St. Paul, MN, June 13, 2025 (GLOBE NEWSWIRE) — With federal cost-cutting and deregulation reshaping workplace safety oversight, the responsibility to protect workers from extreme heat is falling squarely on employers. While OSHA's National Emphasis Program (NEP) on Heat Stress has been extended for another year, the long-anticipated federal heat stress standard is looking less likely than ever. That means worksites will need to rely on existing guidance, industry best practices, and—more than anything—their own commitment to doing what's right.
'The reality is, a federally mandated heat stress standard in the U.S. may not happen anytime soon,' says Greg Schrab, President at Ergodyne, a leader in safety work gear and heat stress prevention. 'But regulation should never be the reason we protect workers. Employers don't need a federal rule to tell them that heat stress is dangerous, or that simple, proven solutions can save lives.'
With extreme heat becoming a predictable threat year after year, safety professionals are stepping up where federal regulations fall short—turning to resources like OSHA's NEP, ANSI/ASSP A10.50-2024, state regulations, and industry safety leaders to build and reinforce heat stress prevention programs that work.
From implementing hydration and rest schedules to providing personal cooling gear, the industry's best practices are well-documented. The challenge for many employers isn't knowing what to do—it's making sure it gets done.
Randy Milliron, Safety Manager for the City of Gillette, Wyoming, agrees. He points to time-tested basics as the foundation of his program. 'It will sound so rudimentary, but if you keep to the classics you can safely work outside when the thermostat starts to rise. Drinking plenty of fluids, monitoring urine output and color, taking breaks in the shade, and looking out for your co-workers are the key things to help you stay cool and hydrated.'
To help worksites put prevention into practice, Ergodyne is expanding its cooling gear and heat stress solutions with new advancements in wearable cooling, flame-resistant cooling PPE, and turnkey heat stress prevention kits. But gear is only part of the equation. The St. Paul, MN-based worksite safety leader and cooling category pioneer is in the field working alongside employers to provide on-site education in support of company heat stress prevention programs.
'Unless you are attending safety conferences and rubbing elbows with the vendors who provide this type of PPE, you might not know of all the advancements that have been made in these product lines,' Milliron says. 'So, I believe it is necessary, if you are a safety professional, to find those subject-matter experts who specialize in cooling products and create long-lasting friendships with them.'
Milliron has seen firsthand how proactive prevention can make a difference. 'Last summer we had a seasonal employee try to work through the early signs and symptoms of heat illness. By the time I arrived, he was in bad shape. We moved him into the air-conditioned office and applied ice packs and a cooling towel to his groin and neck. It took a very long time for his symptoms to subside, but the cooling towel did the trick at lowering his core body temperature.'
By leveraging proven cooling solutions and industry-backed guidance, safety leaders can make sure their teams stay safe, stay productive, and stay protected—regardless of what happens at the federal level.
'In the absence of federal action, it's up to employers to step up,' says Lexi Engelbart, Product Manager at Ergodyne and Vice Chair of the International Safety Equipment Association's (ISEA) Heat Stress Solutions Group. 'Not because they have to, but because it's the right thing to do.'
For more heat stress education, including signs, symptoms, and solutions, visit ergodyne.com/heat-stress.
ABOUT ERGODYNE
Since 1983, Tenacious Holdings, Inc. (dba Ergodyne, a Klein Tools Company) has pioneered the development of products that Make The Workplace A Betterplace™. What started with just one product has grown into a line of top flight, battle-tested, Tenacious Work Gear®; all precision crafted to provide protection, promote prevention and manage the elements for workers on jobsites the world over. The current lineup is extensive and constantly growing: ProFlex® Hand Protection, ProFlex® Knee Pads, ProFlex® Supports, Skullerz® Head & Face Protection, Skullerz® Eye Protection, Trex® Traction, KREW'D® Skin Protection, Chill-Its® Cooling Products, N-Ferno® Warming Products, GloWear® Hi-Vis Apparel, Squids® Lanyards, Arsenal® Gear and Tool Storage, and SHAX® Portable Work Shelters.
Originally posted on: www.ergodyne.com
Attachment New Heat Stress Hazard Solutions
Disclaimer: The above press release comes to you under an arrangement with GlobeNewswire. Business Upturn takes no editorial responsibility for the same.
Ahmedabad Plane Crash
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Upturn
3 hours ago
- Business Upturn
Celldex Presents Data Demonstrating Profound Long Term Improvement in Angioedema in Barzolvolimab Phase 2 Study in Chronic Spontaneous Urticaria at EAACI 2025
77% of patients (150 mg Q4W) treated with barzolvolimab who had angioedema at baseline were angioedema free at Week 52 (150 mg Q4W) Data further support barzolvolimab clinical benefit to patients with CSU HAMPTON, N.J., June 14, 2025 (GLOBE NEWSWIRE) — Celldex Therapeutics, Inc. (NASDAQ:CLDX) today announced data demonstrating that barzolvolimab profoundly improves angioedema at 52 weeks in the Company's Phase 2 clinical trial in chronic spontaneous urticaria (CSU). Angioedema, characterized by swelling of the deeper dermal layers of the skin and mucous membranes, is a painful, debilitating symptom of CSU that has significant impact on quality of life. It commonly affects the face (lips and eyelids), hands, feet, and genitalia but can also involve the tongue, uvula, soft palate, and pharynx1. The data were presented today by Dr. Martin Metz, Professor, Department of Dermatology and Allergy, Head of Translational Research and Deputy Head of Clinical Trials at Charité – Universitätsmedizin in Berlin, in an oral presentation at the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2025. Celldex previously announced that the Phase 2 study in CSU met its primary and secondary endpoints at 12 weeks with clinically meaningful and statistically significant decreases in UAS7 (weekly urticaria activity score) compared to placebo across multiple dose groups, including improvements in quality of life and angioedema measurements, and demonstrated a favorable safety profile. The data presented today further support these results by demonstrating improvements in AAS7 (weekly angioedema activity score) and additional measures of angioedema control over the 52 week treatment period. AAS7 measures the frequency and intensity of angioedema episodes, where higher scores indicate increased angioedema activity. 'The majority of patients with severe CSU suffer with angioedema, which is often extremely painful and causes disfigurement, dramatically impacting quality of life,' said Diane C. Young, MD, Senior Vice President and Chief Medical Officer of Celldex Therapeutics. 'Consistent with previously reported clinical outcomes, we observed rapid, profound angioedema relief with barzolvolimab treatment and this benefit continued to improve over 52 weeks of therapy for patients. These data add to the unprecedented 76 week efficacy and safety data we presented yesterday at EAACI and continue to support barzolvolimab's potential to redefine the treatment landscape and meet the goals of CSU therapy—rapid, profound, durable complete response and improved quality of life across a broad patient population.' Summary of Key Findings: Patients on study had severe CSU. Over 70% of patients had a weekly urticaria activity score (UAS7) greater than 28 at baseline and reported very high rates of angioedema at baseline. Barzolvolimab demonstrated rapid, robust and durable improvements in angioedema symptoms over the treatment period. At Week 52, an 86% mean reduction from baseline was reported for 150 mg Q4W arm and an 82% reduction was reported for the 300 mg Q8W. Up to 77% of patients treated with barzolvolimab who had angioedema at baseline were angioedema free (AAS7=0) at Week 52. Patients treated with barzolvolimab were angioedema free up to 72% of the time over the 52 week treatment period. Up to 87% of patients reported clinically meaningful improvement ( > 8 point) in AAS7 at Week 52. 1 DermNet . About Barzolvolimab Barzolvolimab is a humanized monoclonal antibody that binds the receptor tyrosine kinase KIT with high specificity and potently inhibits its activity. KIT is expressed in a variety of cells, including mast cells, which mediate inflammatory responses such as hypersensitivity and allergic reactions. KIT signaling controls the differentiation, tissue recruitment, survival and activity of mast cells. In certain inflammatory diseases, such as chronic urticaria, mast cell activation plays a central role in the onset and progression of the disease. Barzolvolimab is currently being studied in chronic spontaneous urticaria (CSU), chronic inducible urticaria (CIndU), prurigo nodularis (PN), eosinophilic esophagitis (EOE) and atopic dermatitis (AD), with additional indications planned for the future. About the Phase 2 CSU Study The randomized, double-blind, placebo-controlled, parallel group Phase 2 study evaluated the efficacy and safety profile of multiple dose regimens of barzolvolimab in patients with CSU who remain symptomatic despite antihistamine therapy, to determine the optimal dosing strategy. 208 patients were randomly assigned on a 1:1:1:1 ratio to receive subcutaneous injections of barzolvolimab at 75 mg every 4 weeks, 150 mg every 4 weeks, 300 mg every 8 weeks or placebo during a 16-week placebo-controlled treatment period. After 16 weeks, patients then entered a 36-week active treatment period, in which patients receiving placebo or the 75 mg dose were randomized to receive barzolvolimab 150 mg every 4 weeks or 300 mg every 8 weeks; patients already randomized to the 150 mg and 300 mg treatment arms remained on the same regimen as during the placebo-controlled treatment period. After 52 weeks, patients entered a follow-up period for an additional 24 weeks. Barzolvolimab achieved the primary efficacy endpoint of the study—a statistically significant mean change from baseline to Week 12 in UAS7 (weekly urticaria activity score) compared to placebo at all dose levels. For additional information on this trial (NCT05368285), please visit About the Phase 3 Program Celldex is currently conducting a global Phase 3 Program for barzolvolimab in CSU, consisting of two Phase 3 trials (EMBARQ-CSU1; NCT06445023 and EMBARQ-CSU2; NCT06455202) designed to establish the efficacy and safety of barzolvolimab in adult patients with CSU who remain symptomatic despite H1 antihistamine treatment. The studies also include patients who remain symptomatic after treatment with biologics. Enrollment is underway. About Chronic Spontaneous Urticaria (CSU) CSU is characterized by the occurrence of hives or wheals for 6 weeks or longer without identifiable specific triggers or causes. The activation of the mast cells in the skin (release of histamines, leukotrienes, chemokines) results in episodes of itchy hives, swelling and inflammation of the skin that can go on for years or even decades. Current therapies provide symptomatic relief only in some patients. About Celldex Celldex is pioneering new horizons in immunology to deliver life-changing therapies. We are relentless in our pursuit of novel antibody-based treatments that engage the human immune system and directly affect critical pathways to improve the lives of patients with allergic, inflammatory and autoimmune disorders. Visit Forward Looking Statement This release contains 'forward-looking statements' made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements are typically preceded by words such as 'believes,' 'expects,' 'anticipates,' 'intends,' 'will,' 'may,' 'should,' or similar expressions. These forward-looking statements reflect management's current knowledge, assumptions, judgment and expectations regarding future performance or events. Although management believes that the expectations reflected in such statements are reasonable, they give no assurance that such expectations will prove to be correct or that those goals will be achieved, and you should be aware that actual results could differ materially from those contained in the forward-looking statements. Forward-looking statements are subject to a number of risks and uncertainties, including, but not limited to, our ability to successfully complete research and further development and commercialization of Company drug candidates, including barzolvolimab (also referred to as CDX-0159), in current or future indications; the uncertainties inherent in clinical testing and accruing patients for clinical trials; our limited experience in bringing programs through Phase 3 clinical trials; our ability to manage and successfully complete multiple clinical trials and the research and development efforts for our multiple products at varying stages of development; the availability, cost, delivery and quality of clinical materials produced by our own manufacturing facility or supplied by contract manufacturers, who may be our sole source of supply; the timing, cost and uncertainty of obtaining regulatory approvals; the failure of the market for the Company's programs to continue to develop; our ability to protect the Company's intellectual property; the loss of any executive officers or key personnel or consultants; competition; changes in the regulatory landscape or the imposition of regulations that affect the Company's products; our ability to continue to obtain capital to meet our long-term liquidity needs on acceptable terms, or at all, including the additional capital which will be necessary to complete the clinical trials that we have initiated or plan to initiate; and other factors listed under 'Risk Factors' in our annual report on Form 10-K and quarterly reports on Form 10-Q. All forward-looking statements are expressly qualified in their entirety by this cautionary notice. You are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date of this release. We have no obligation, and expressly disclaim any obligation, to update, revise or correct any of the forward-looking statements, whether as a result of new information, future events or otherwise. Company ContactSarah CavanaughSenior Vice President, Corporate Affairs & Administration(508) 864-8337 [email protected]
Yahoo
7 hours ago
- Yahoo
ThinkCareBelieve: Week 21 of America's Progress under President Trump
Washington D.C., June 14, 2025 (GLOBE NEWSWIRE) -- You can find the article here: has published an article on the 21st week of America under the leadership of President Donald J. Trump. America is making strong progress toward prosperity and ThankCareBelieve's article shows this weeks numbers and indicators supporting that. Prices are going down. Tariffs are working. Inflation is gone. The economy is strong and once the One Big Beautiful Bill is passed, the economy will be booming. The article has a report by Maria Bartiromo that the CPI (Consumer Price Index) is out and the numbers are better than expected, surprising everyone. The trade deal with China is now complete, allowing China's markets to open up for American products which will help American business soar. The article shows this week's Los Angeles riots have sparked several investigations where they actually were paid anarchy by those wanting to disrupt American 21st week ends on Flag Day, the 25th Anniversary of the U.S. Army and the Birthday of President Donald J. Trump. The article shows how strong America has become with record number of enlistments and re-enlistments, President Trump attended an Invest in America Event and the President signing an end to costly and impractial EV Mandates. The Halt Fentanyl Act has been passed and is ready to be signed. The article also covers Secretary Kennedy's huge steps to restore public trust by appointing a new board to the Advisory Committee for Immunization Practices (ACIP), including the appointment of Dr. Robert Malone, M.D. is an outlook. ThinkCareBelieve's mission for Peace advocacy facilitates positive outcomes and expanded possibilities. To achieve Peace, we will find the commonalities between diverse groups and bring the focus on common needs, working together toward shared goals. Activism is an important aspect of ThinkCareBelieve, because public participation and awareness to issues needing exposure to light leads to justice. Improved transparency in government can lead to changes in policy and procedure resulting in more fluid communication between the public and the government that serves them. America needs hope right now, and Americans need to be more involved in their government. ### CONTACT: CONTACT: Joanne COMPANY: ThinkCareBelieve EMAIL: joanne@ WEB: in to access your portfolio
Yahoo
9 hours ago
- Yahoo
Jewish Family Services receives $400K for opioid use support program
Niagara County and New York State have awarded Jewish Family Services $400,000 to provide services to those impacted by opioid use. The county awarded a $350,000 two-year grant to JFS for a comprehensive career support and care management recovery program at its Niagara Falls office. The state Office of Faith and Nonprofit Development Services awarded $50,000 to develop a community resource room for families served by care coordination and health home programs and for new American families. Both plan to start later this year. 'From addressing behavioral health and wellness needs to help prevent relapse and post-lasting recovery, to providing a safe space for families to work toward securing self-sustainability, JFS staff is committed to empowering individuals with the resources needed for long-term success,' said Jewish Family Services CEO Molly Carr in a statement. Around 12% of clients enrolled in JFS's Niagara County-based health home program have suffered from opioid use disorder, substance abuse, and other mental health conditions. It helped between 250 and 300 clients in the county in 2023. 'While those in recovery are faced with many challenges, one of the biggest can be getting back into the workforce,' said County Legislator Jesse Gooch, chair of the Community Services Committee. 'The JFS program has a focus on employment services, something that is sorely needed, which is why we were happy to award them grant funding through the opioid settlement fund.' The community resource room will have laptops, internet access, printers, scanners, and noise-cancelling headphones on hand. Case managers will be available by appointment for job application help and technology and interpretation services. JFS opened its Niagara Falls office on Third Street last August, with case workers there working on career services and refugee resettlement programming. It has operated in Buffalo since 1862, starting Niagara County services in 2021. It was one of many area nonprofits that had to cut positions earlier this year after the Trump administration froze funds meant for agencies that help new refugee arrivals. It partnered with four other Buffalo agencies to raise $1.5 million in February and March to cover funding shortfalls.
